Dennis Carney

Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.

Piers Blombery, Thomas E Lew, Michael A Dengler, Ella R Thompson, Victor S Lin, Xiangting Chen, Tamia Nguyen, Ashish Panigrahi, Sasanka Mithila Handunnetti, Dennis Carney, David A Westerman, Constantine S Tam, Jerry M Adams, Andrew H Wei, David Ching Siang Huang, John F Seymour, Andrew Roberts, Mary Ann Anderson

Journal article  |  2021  |  Blood

The BCL2 inhibitor venetoclax has established therapeutic roles in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia. ..

PF388 HAT-PCR IS MORE SENSITIVE THAN FLOW FOR QUANTIFYING MRD IN CHRONIC LYMPHOCYTIC LEUKEMIA

A Morley, S Latham, E Hughes, B Kuss, S Grist, R Hall, C Tam, D Carney, G Cull, S Mulligan, S Bailey, M Sartor, D Gottlieb

Journal article  |  2019  |  HemaSphere

AN UNDETECTABLE PB MRD STATUS SHOULD BE THE THERAPEUTIC GOAL WITH VENETOCLAX THERAPY IN RELAPSED/ REFRACTORY CLL

SM Handunnetti, TE Lew, VS Lin, MA Anderson, D Carney, M Wolf, N Came, S Juneja, D Westerman, CS Tam, AW Roberts, JF Seymour

Conference Proceedings  |  2019  |  Hematological Oncology

Serial Minimal Residual Disease Evaluation in Patients with Chronic Lymphocytic Leukemia Under Long-Term Venetoclax Treatment

Thomas Lew, Mary Ann Anderson, Constantine S Tam, Sasanka Handunnetti, Dennis Carney, Max Wolf, Surender Juneja, David Alan Westerman, Andrew W Roberts, John F Seymour

Conference Proceedings  |  2018  |  BLOOD

Abstract Background The selective BCL2 inhibitor venetoclax (Ven) achieves an overall response rate of approximatel..

Long Term Outcomes of Venetoclax Therapy for Complex Karyotype Relapsed/Refractory Chronic Lymphocytic Leukemia

Thomas Lew, Mary Ann Anderson, Constantine S Tam, Sasanka Handunnetti, Dennis Carney, Meaghan Wall, Andrew W Roberts, John F Seymour

Conference Proceedings  |  2018  |  Blood

Abstract Background The selective BCL2 inhibitor venetoclax (Ven) achieves an overall response rate of approximatel..

Plasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitors

Kah-Lok Chan, Piers Blombery, Kate Jones, Stephen Lade, Dennis Carney, Huy Tran, John F Seymour, Constantine S Tam

Journal article  |  2017  |  BRITISH JOURNAL OF HAEMATOLOGY

Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib

Khai Li Chai, Gail Rowan, John F Seymour, Kate Burbury, Dennis Carney, Constantine S Tam

Journal article  |  2017  |  LEUKEMIA & LYMPHOMA

The management of AF represents a major challenge in patients with CLL, especially in elderly patients with multiple comorbidities..

Disseminated visceral varicella zoster virus presenting with the constellation of colonic pseudo-obstruction, acalculous cholecystitis and syndrome of inappropriate ADH secretion

MR Braude, JA Trubiano, A Heriot, M Dickinson, D Carney, JF Seymour, CS Tam

Journal article  |  2016  |  INTERNAL MEDICINE JOURNAL

Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy

Thomas E Lew, Chan Y Cheah, Dennis A Carney, H Miles Prince, Max Wolf, Ali Bazargan, E Henry Januszewicz, Robin Filshie, David Westerman, John F Seymour, Constantine S Tam

Journal article  |  2016  |  LEUKEMIA & LYMPHOMA

Despite its efficacy in prospective trials, full dose fludarabine, cyclophosphamide and rituximab (FCR) may be too toxic for elder..

Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20( ) lymphoid malignancies

Andrew W Roberts, Ranjana H Advani, Brad S Kahl, Daniel Persky, John W Sweetenham, Dennis A Carney, Jianning Yang, Todd B Busman, Sari H Enschede, Roderick A Humerickhouse, John F Seymour

Journal article  |  2015  |  BRITISH JOURNAL OF HAEMATOLOGY

The oral BCL2 inhibitor navitoclax has moderate single-agent efficacy in chronic lymphocytic leukaemia (CLL) and minor activity in..